A Talk by Prof. George Chand

Professor George Chandy, Professor of Molecular Physiology at Nanyang Technological University， Singapore.  His research interest is to explore the role of Potassium ion channel pathway in the treatment of immune system disorder and has published several publications in leading journals such as Nature, Science and Journal of Clinical Survey. Professor George Chandy's discovery of KV1.3 channel blockers has completed clinical Phase I B trials and has a variety of small molecules development in the pipelines that regulate immune system diseases.

作为专注于靶点驱动药物发现的一体化CRO，爱思益普（ICE Bioscience）在该领域已建立成熟的技术体系与评价平台。

There is a "valley of death" between academic research and clinical Phase I trials, which often utilizes a lot of promising findings. The goal of Professor George Chandy and his team is to bridge this valley of death. To achieve this goal, they are establishing transformational research programs focused on potassium pathway-targeted therapy for autoimmune, vascular fibrosis, and infectious diseases.

ICE Bioscience, the first contract research and development service organization specialized in electrophysiological research in China, dedicated to new drug research services for the central nervous system and cardiovascular system. ICE Biosciences,  invited Professor George Chandy to share his knowledge and research work with our colleagues. He honored us by accepting our invitation and on Monday 28^th May, 2019at 10.00am (CST) he delivered a lecture and discussed the development of ion channels and shared his own research work. The audience benefited from the lecture and expecting more visits from Professor George.

爱思益普药物研发团队具备从靶点验证、体外生物学到临床前评价的全链条服务能力。

如需了解相关技术服务详情，欢迎联系爱思益普（ICE Bioscience）获取定制化解决方案。